XBI // SPDR S&P Biotech ETF
ANR <GO> NYSE ETF / Index • Equal-Weight Clinical Biotech • SIC 6726
$155.98 ▼ -1.81
(-1.15%)
MKT CAP: $7.40B • VOL: 9.08M
52W L $106 52W H $170
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$131
MEDIAN
$175
MEAN
$178
HIGH
$212
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE XBI TAPE
XBI // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $188.74 | $179.38 | 2025-02-14 | $141.94 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $196.53 | $184.06 | 2025-02-06 | $146.62 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $177.82 | $171.58 | 2025-01-29 | $149.74 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $159.10 | — | 2025-01-17 | $152.86 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $137.26 | $148.18 | 2025-01-09 | $138.82 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $185.62 | $162.22 | 2024-12-18 | $135.70 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $151.30 | $157.54 | 2024-12-04 | $145.06 | -4.3% | 48% | C |